2021 U.S.-Booked Air Volume: $9.2 million
2021 Global T&E: $22 million
Primary Global Payment Provider: Bank of America
Primary Global Expense Supplier: SAP Concur
Global Travel Risk Management Supplier: WorldAware
Consolidated Global TMC: BCD
Japan-headquartered Takeda Pharmaceutical spent 2020 implementing BCD Travel across 70 markets to consolidate to a single global travel management company. In 2021 it trained travelers on that new program with a strong focus on wellness and sustainability. The company first and foremost emphasized that travelers should have a safe and comfortable experience when they embarked on their ‘first’ business trip after the company’s general travel hiatus during the Covid-19 pandemic.
To support that goal, Takeda implemented the Roadmap app across the organization and implemented virtual payment for non-employee travelers. Takeda projected it will spend $12 million on U.S. point-of-sale air volume for 2022. After the many changes precipitated by the pandemic, the company could not predict if or when it would return to previous travel levels, which BTN estimated to be $54 million in 2019.
The company’s goals for 2022 are to continue to focus on traveler wellness and the health of the planet. Takeda this year implemented a specialized patient-centric travel program Takeda in collaboration with BCD’s Life Sciences Center of Excellence and for which the company was recognized by BTN as a leader in managed travel innovation.